Orioled Hub

Orioled Hub's journey began in 2009 with the establishment of Orioled International in Singapore. The primary goal was to create a robust pharmaceutical business and service system in the burgeoning Southeast Asian market. In 2015, Orioled Hub expanded its footprint into Vietnam through TV TPI, marking a significant milestone. This strategic move allowed Orioled Hub to penetrate a high-potential market, thereby extending its network and influence in the pharmaceutical industry. The year 2022 witnessed the formation of the OH Institute (OHI), dedicated to research and training, underlining Orioled Hub commitment to innovation and education in the pharmaceutical sector. In 2023, Orioled Hub embarked on an ambitious project to establish the Reiwapharm pharmaceutical manufacturing plant, adhering to European standards. This facility is projected to commence operations in 2026, setting a new benchmark for quality and excellence in pharmaceutical manufacturing. Orioled Hub has established subsidiary companies across Asia, including Hong Kong and Europe, to support its rapid growth. These strategic expansions have laid a solid foundation for Orioled Hub to evolve into a regional pharmaceutical conglomerate with a global vision. Orioled Hub continues to pursue excellence, innovation, and growth, aiming to significantly impact the global pharmaceutical landscape. In Vietnam, Orioled Hub is a brand registered for protection by TV TPI.